Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Liver Diseases

  Free Subscription


11.08.2025

2 AJR Am J Roentgenol
2 Anticancer Res
1 Biochem Biophys Res Commun
2 BMC Cancer
6 BMC Gastroenterol
9 Clin Res Hepatol Gastroenterol
3 Dig Dis Sci
2 Eur J Pediatr
2 Eur Radiol
2 Gut
1 Indian J Gastroenterol
1 J Comput Assist Tomogr
1 J Gastroenterol Hepatol
9 J Hepatol
3 PLoS One
2 Radiology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. ZHANG LX, Burgio MD, Vilgrain V, Fang C, et al
    Quantitative Ultrasound and Ultrasound-Based Elastography for Chronic Liver Disease: Practical Guidance, From the AJR Special Series on Quantitative Imaging.
    AJR Am J Roentgenol. 2024 Sep 11. doi: 10.2214/AJR.24.31709.
    PubMed         Abstract available

  2. CHIU SH, Kesselman A, Yoon L, Kamaya A, et al
    LI-RADS CT/MRI Radiation Treatment Response Algorithm Version 2024: Category Redistribution and Short-Term Outcomes in Patients Undergoing Y-90 Radioembolization for HCC.
    AJR Am J Roentgenol. 2025 Apr 30. doi: 10.2214/AJR.25.32745.
    PubMed         Abstract available


    Anticancer Res

  3. FUKUTOMI S, Sakai H, Goto Y, Hashimoto K, et al
    Short- and Long-term Outcomes of Laparoscopic Versus Open Repeat Hepatectomy for Hepatocellular Carcinoma.
    Anticancer Res. 2025;45:3523-3530.
    PubMed         Abstract available

  4. SAKAI H, Goto Y, Fukutomi S, Arai S, et al
    Standardized Technique for Minimally Invasive Right Posterior Sectionectomy for Hepatocellular Carcinoma: A Propensity Score-matched Study.
    Anticancer Res. 2025;45:3497-3510.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  5. LI Q, Zhang Q, Ren A, Zhang H, et al
    Analysis and verification of potential ferroptosis-related diagnostic markers in the early stage of metabolic dysfunction-associated steatohepatitis.
    Biochem Biophys Res Commun. 2025;779:152406.
    PubMed         Abstract available


    BMC Cancer

  6. QIU Y, Zhang H, Yu X, Pan J, et al
    Decoding the epigenetic-immune nexus in hepatocellular carcinoma: a Mendelian randomization study reveals BTN3A2, S100A12 and TRIM27 as white blood cell regulators.
    BMC Cancer. 2025;25:1282.
    PubMed         Abstract available

  7. LIU J, Fang K, Pei S, Gao Y, et al
    The role of prognostic nutrition index in the prognosis of patients with advanced hepatocellular carcinoma who received first-line therapy.
    BMC Cancer. 2025;25:1258.
    PubMed         Abstract available


    BMC Gastroenterol

  8. LI Y, Zhang D, Tian T, Xie J, et al
    Relationship between gut microbiota dysbiosis and bile acid in patients with hepatitis B-induced cirrhosis.
    BMC Gastroenterol. 2025;25:552.
    PubMed         Abstract available

  9. SONG F, Wu XL, Wei BH
    Prognostic value of neutrophil-to-lymphocyte ratio in septic patients with liver cirrhosis: a cohort study.
    BMC Gastroenterol. 2025;25:549.
    PubMed         Abstract available

  10. INMUTTO N, Jantarangkoon A, Nimitrungtawee N, Sriwicha N, et al
    Doppler ultrasound and 2D shear wave ultrasound elastography for liver fibrosis evaluation in Fontan-associated liver disease.
    BMC Gastroenterol. 2025;25:553.
    PubMed         Abstract available

  11. ZHENG X, Wang H
    Association between glycated hemoglobin/high-density lipoprotein ratio and nonalcoholic fatty liver disease in a U.S. nondiabetic population: a cross-sectional study based on NHANES 2017-2020 data.
    BMC Gastroenterol. 2025;25:567.
    PubMed         Abstract available

  12. ALNEES M, Awwad M, Najajra D, Darwish A, et al
    Predictive factors for metabolic syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
    BMC Gastroenterol. 2025;25:562.
    PubMed         Abstract available

  13. NGUYEN KP, Nguyen XV, Doan TH
    Impact of timing of endoscopy on clinical outcomes in cirrhotic patients with esophageal variceal bleeding: a monocentric retrospective study from Vietnam.
    BMC Gastroenterol. 2025;25:565.
    PubMed         Abstract available


    Clin Res Hepatol Gastroenterol

  14. SUALEHEEN A, Tan SY, Daly RM, Georgousopoulou E, et al
    Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population.
    Clin Res Hepatol Gastroenterol. 2025;49:102649.
    PubMed         Abstract available

  15. LU Y, Yi F, Chen W, Tan X, et al
    Involvement of oxidative stress, lipid dysmetabolism and gut microbiol dysbiosis in oxaliplatin-induced fatty liver disease: evidence from a tree shrew model.
    Clin Res Hepatol Gastroenterol. 2025;49:102645.
    PubMed         Abstract available

  16. LUCE E, Messina A, Duclos-Vallee JC
    Hepatic organoids as a platform for liver disease modeling and the development of novel therapies.
    Clin Res Hepatol Gastroenterol. 2025;49:102647.
    PubMed         Abstract available

  17. JIANG Y, Huang Y, Hu X, Chen G, et al
    The role of tumor microenvironment in lenvatinib resistance of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2025;49:102642.
    PubMed         Abstract available

  18. CARRIER P, Chalange M, Girard M, Premaud A, et al
    Liver fibrosis evaluation in patients with psychiatric diseases.
    Clin Res Hepatol Gastroenterol. 2025;49:102636.
    PubMed         Abstract available

  19. LANTHIER N
    Does the benefit of optimal MASH treatment depend on a reduction in myosteatosis?
    Clin Res Hepatol Gastroenterol. 2025;49:102640.
    PubMed         Abstract available

  20. WANG P, Guo G, Jiang S, Ding D, et al
    Glucocorticoids accelerate the reduction of disease severity and biochemical parameters in drug-induced liver injury: Assess the causal relationship using the updated RUCAM scale.
    Clin Res Hepatol Gastroenterol. 2025;49:102635.
    PubMed         Abstract available

  21. ZHENG SS, Zhang D, Wu JF, Chen H, et al
    Circulating tumor DNA in peripheral blood may predict the efficacy of immune-targeted therapy in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2025;49:102632.
    PubMed         Abstract available

  22. XU X, Zhao H, Zhang J, Yan H, et al
    Interleukin-22 ameliorates alcohol-associated liver fibrosis via Nrf2-ARE signaling: mechanistic insights and clinical correlations.
    Clin Res Hepatol Gastroenterol. 2025;49:102617.
    PubMed         Abstract available


    Dig Dis Sci

  23. CULLARO G, Allegretti AS, Patidar KR, Verna EC, et al
    Applying Metabolomics and Aptamer-Based Proteomics to Determine Pathophysiologic Differences in Decompensated Cirrhosis Patients Hospitalized with Acute Kidney Injury.
    Dig Dis Sci. 2025 Aug 1. doi: 10.1007/s10620-025-09223.
    PubMed         Abstract available

  24. ALDIABAT M, Aljabiri Y, Aleyadeh W, Madi MY, et al
    Branched-Chain Amino Acid Supplementation and Clinical Outcomes in Liver Cirrhosis: A Propensity Score-Matched Multicenter Retrospective Cohort Study.
    Dig Dis Sci. 2025 Aug 5. doi: 10.1007/s10620-025-09258.
    PubMed         Abstract available

  25. BAKER B, Aridi TG, Patel M, Carter A, et al
    Social Determinants Are Important Barriers to Completion of the Liver Transplant Pathway and Are Associated with Waitlisting and Mortality in Hepatocellular Carcinoma.
    Dig Dis Sci. 2025 Aug 6. doi: 10.1007/s10620-025-09278.
    PubMed         Abstract available


    Eur J Pediatr

  26. LI Y, Liu R, An Y, He F, et al
    Markers of body fat, the mediating role of alanine aminotransferase, and their association with the risk of metabolic dysfunction-associated steatotic liver disease.
    Eur J Pediatr. 2025;184:524.
    PubMed         Abstract available

  27. BEHAIRY OGA, El-Hamshary AM, Torky AA, Khashaba RA, et al
    Role of plasma Von-Willebrand factor in children with chronic liver diseases.
    Eur J Pediatr. 2025;184:532.
    PubMed         Abstract available


    Eur Radiol

  28. LI Y, Chen Y, Wu Z, Shi Y, et al
    Noninvasive MRI imaging feature-based prediction of intratumoral tertiary lymphoid structure maturity in hepatocellular carcinoma: a multicenter retrospective study.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11902.
    PubMed         Abstract available

  29. CHE F, Li Q, Ren W, Tang H, et al
    3D fractal dimension analysis of CT imaging for microvascular invasion prediction in hepatocellular carcinoma.
    Eur Radiol. 2025 Aug 7. doi: 10.1007/s00330-025-11878.
    PubMed         Abstract available


    Gut


  30. Correction: Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
    Gut. 2025;74:e18.
    PubMed        

  31. FONTANELLAS A, Berraondo P, Urigo F, Jerico D, et al
    RNA-based therapies in liver metabolic diseases.
    Gut. 2025;74:1514-1527.
    PubMed         Abstract available


    Indian J Gastroenterol

  32. XIANG Q, Ao Y, Jia Q, Lu M, et al
    Clinical applications of hyperspectral imaging in gastroenterology and hepatology: A systematic review.
    Indian J Gastroenterol. 2025 Aug 6. doi: 10.1007/s12664-025-01836.
    PubMed         Abstract available


    J Comput Assist Tomogr

  33. MROUEH N, Cao J, Srinivas Rao S, Ghosh S, et al
    Response Assessment in Hepatocellular Carcinoma: A Primer for Radiologists.
    J Comput Assist Tomogr. 2025 Aug 7. doi: 10.1097/RCT.0000000000001789.
    PubMed         Abstract available


    J Gastroenterol Hepatol

  34. HEGAZY RA
    Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics.
    J Gastroenterol Hepatol. 2025 Aug 3. doi: 10.1111/jgh.70037.
    PubMed         Abstract available


    J Hepatol

  35. VERMA N, Angeli P, Jalan R
    Stratification, Therapeutic Targeting and Towards Personalised Care in Cirrhosis.
    J Hepatol. 2025 Aug 1:S0168-8278(25)02378-5. doi: 10.1016/j.jhep.2025.
    PubMed        

  36. BJORN AB, Jensen MD, Pero A, Villadsen GE, et al
    Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02390-6. doi: 10.1016/j.jhep.2025.
    PubMed        

  37. NADIM MK, Kellum JA, Durand F
    From Protocol to Precision: The Evolving Diagnosis of Hepatorenal Syndrome.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02393-1. doi: 10.1016/j.jhep.2025.
    PubMed        

  38. HE J, Zhang M, Shi Y, Ji Z, et al
    Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02382-7. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available

  39. PIANO S, Patidar KR, Juanola A
    Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: enough, but not too much.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02395-5. doi: 10.1016/j.jhep.2025.
    PubMed        

  40. CABIBBO G, Celsa C, Bhoori S, Reiberger T, et al
    Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02386-4. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available

  41. ZHANG R, Su L, Fu M, Wang Z, et al
    Corrigendum to: 'CD177(+) cells produce neutrophil extracellular traps that promote biliary atresia' (J Hepatol [2022] 77:1299-1310).
    J Hepatol. 2025 Aug 4:S0168-8278(25)02281-0. doi: 10.1016/j.jhep.2025.
    PubMed        

  42. BREVINI T, Swift L, Reynolds H, Ong J, et al
    Successful AAV8 gene therapy on hepatic ex situ machine perfusion for mitochondrial neurogastrointestinal encephalomyopathy.
    J Hepatol. 2025 Aug 5:S0168-8278(25)02388-8. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available

  43. BOT KK, Ezzafzafi S, Lantinga MA
    Not all DOACs are created equal, revisiting the safety of rivaroxaban for the prevention of portal hypertension-related complications.
    J Hepatol. 2025 Aug 5:S0168-8278(25)02396-7. doi: 10.1016/j.jhep.2025.
    PubMed        


    PLoS One

  44. NASIR M, Xu Y, Hasenstab K, Yechoor A, et al
    Liver MRI proton density fat fraction inference from contrast enhanced CT images using deep learning: A proof-of-concept study.
    PLoS One. 2025;20:e0328867.
    PubMed         Abstract available

  45. RIVADENEIRA J, Fuenmayor-Gonzalez L, Hasnaoui A, Ortiz D, et al
    Prognostic factors associated with recurrence in patients undergoing surgery for hepatic cystic echinococcosis: A systematic review protocol.
    PLoS One. 2025;20:e0329235.
    PubMed         Abstract available

  46. BOUSHEHRI YG, Meymanatabadi Z, Tanha AE, Azami P, et al
    Association of triglyceride glucose-body mass index (TyG-BMI) with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0324483.
    PubMed         Abstract available


    Radiology

  47. CANNELLA R
    MRI Quantitative Features: A Bridge to Hepatocellular Carcinoma Tumor Profiling.
    Radiology. 2025;316:e252216.
    PubMed         Abstract available

  48. MATUSCHEWSKI NJ, Sobirey R, Revzin M, Zeevi T, et al
    Noninvasive Tumor Profiling: Quantitative Contrast-Enhanced MRI Markers Predict PD-L1 and CTNNB1 Status in Hepatocellular Carcinoma.
    Radiology. 2025;316:e242750.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.